Comparative efficacy should have a "formal role in drug licensing"
08 September 2011
Alex Shimmings
Please Login to read the full article.
08 September 2011
Alex Shimmings
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA Panel: Regeneron's Arcalyst not ready for gout
- US Capitol Capsule: FDA cuts shortages, improves user fee goals, while Medicare makes big bust
- Drug makers butt heads on US FDA's proposed biosimilars guidances
- Do global clinical trials make the $100-200mn Indian NCE a mirage?
ANALYSIS
Other Informa Analysis
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
